Trevena, Inc. (TRVN)
| Market Cap | 11.51K |
| Revenue (ttm) | 546.00K -83.0% |
| Net Income | -34.04M |
| EPS | -42.72 |
| Shares Out | 958.79K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 257 |
| Open | 0.0120 |
| Previous Close | 0.0120 |
| Day's Range | 0.0120 - 0.0120 |
| 52-Week Range | 0.0003 - 1.5010 |
| Beta | -1.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Trevena
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managin... [Read more]
Financial Performance
Financial StatementsNews
Trevena downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao downgraded Trevena (TRVN) to Neutral from Buy with an unchanged price target of $5. Following the announcement of reducing Olinvyk’s commercial support to preserve...
Trevena reports Q3 EPS ($5.79) vs ($14.20) last year
Reports Q3 revenue $283,000 vs $180,000 last year
Trevena Reports Third Quarter 2024 Results and Provides Business Update
CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...
Trevena Quarterly report: Q3 2024
Trevena has published its Q3 2024 quarterly earnings report on November 7, 2024.
Trevena Earnings release: Q3 2024
Trevena released its Q3 2024 earnings on November 7, 2024, summarizing the period's financial results.
Trevena receives Nasdaq delisting notification
Trevena announced that on October 4, 2024 the company received notice that the Nasdaq Hearings Panel had determined to delist the company’s common stock from The Nasdaq Stock Market LLC…
Trevena Announces Receipt of Nasdaq Delisting Notification
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Trevena (TRVN), 1,645% surge in interest Telesis Bio (TBI...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Summit Therapeutics (SMMT), 2,594% surge in interest Trev...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Revance Therapeutics (RVNC), 825% surge in interest Treve...
Trevena trading halted, news pending
19:50 EDT Trevena trading halted, news pending
Trevena announces 1-for-25 reverse stock split
Trevena announced that it will effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET…
Trevena reports Q2 EPS (23c) vs. (69c) last year
Reports Q2 revenue $325,000 vs. $3.02M last year. “We have continued to advance TRV045 in the second quarter,” said Carrie Bourdow, President and CEO of Trevena. “We believe the most…
Trevena Quarterly report: Q2 2024
Trevena has published its Q2 2024 quarterly earnings report on August 8, 2024.
Trevena Earnings release: Q2 2024
Trevena released its Q2 2024 earnings on August 8, 2024, summarizing the period's financial results.
Trevena announces $2M non-dilutive financing tranche
Trevena announced an amendment to its March 2022 ex-US royalty-based financing with R-Bridge Healthcare Fund. Pursuant to the Amendment, Trevena will receive a $2 million payment from R-Bridge to Trev...
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
Trevena announces preclinical data on TRV045 in two research collaborations
Trevena announced preclinical data from two separate research collaborations. The first from a series of experiments conducted in collaboration with scientists at Virginia Commonwealth University and ...
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
Trevena Reports First Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
Trevena Quarterly report: Q1 2024
Trevena has published its Q1 2024 quarterly earnings report on May 15, 2024.
Trevena Earnings release: Q1 2024
Trevena released its Q1 2024 earnings on May 15, 2024, summarizing the period's financial results.
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
Trevena Earnings release: Q4 2023
Trevena released its Q4 2023 earnings on April 1, 2024, summarizing the period's financial results.
Trevena Annual report: Q4 2023
Trevena has published its Q4 2023 annual report on April 1, 2024.